Company Overview
PetMed Express, Inc. operates as a specialized pet pharmacy entity within the United States, focusing on the distribution of prescription and non-prescription medications, health products, and essential supplies for dogs, cats, and horses. The company functions within the broader Healthcare sector, specifically categorized under the industry of Pharmaceutical Retailers, which implies a reliance on regulatory compliance and a specialized customer base requiring veterinary oversight for many of its offerings. The organization employs 173 individuals to support its operations and maintain its inventory of medical supplies and over-the-counter pet health items. With a market capitalization of $47.72M and annual revenue reaching $186.96M, PetMed Express represents a mid-cap entity in the pharmaceutical retail landscape. These valuation figures indicate a company that holds a significant position relative to its small employee count, suggesting a potentially capital-intensive operational model or a high valuation multiple despite the revenue scale.
Financial Health
The company reported revenue of $186.96M over the trailing twelve months, yet posted a net income of -$64,869,000 and an EBITDA of -$28,806,000, revealing a substantial disconnect between top-line sales and bottom-line profitability. The significant gap between the $186.96M in revenue and the -$64.869M in net income highlights a heavy cost structure where operating expenses and the cost of goods sold consume the vast majority of gross receipts before taxes and interest are even applied. Free cash flow stands at -$18,373,376, indicating that the company is currently burning cash rather than generating liquidity, which limits its financial flexibility for organic expansion or debt reduction without external financing. The gross margin sits at 27.5%, which is a positive indicator of pricing power or product mix, but this is overwhelmed by an operating margin of -25.7% and a profit margin of -34.7%, signaling deep structural inefficiencies or high fixed costs relative to sales. On the balance sheet, the company holds $26.91M in cash against $652,000 in debt, while the debt-to-equity ratio is recorded at 1.99, suggesting a leveraged capital structure where liabilities nearly double the equity base. However, the current ratio of 0.89 indicates that current assets fall short of covering current liabilities, pointing to potential short-term liquidity pressures if cash inflows do not accelerate. Furthermore, the return on equity is -100.6% and the return on assets is -20.3%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -74.33, a figure that implies the market is pricing in a continued period of negative earnings growth or a turnaround expectation that has not yet materialized in the current period. The price-to-book ratio is 1.45, indicating that the market values the company at 145% of its book value, which suggests a premium price tag despite the entity's negative profitability and deteriorating financial performance. Alternative valuation metrics such as the price-to-sales ratio of 0.26 and the EV/EBITDA of -0.74 provide context on how the market weighs revenue quality and enterprise value relative to earnings power, both of which are currently negative. The stock has traded between a 52-week high of $4.32 and a 52-week low of $1.57, meaning the current valuation sits within this depressed trading range, reflecting investor caution regarding the company's financial trajectory. The beta of 0.73 indicates that the stock exhibits lower volatility relative to the broader market, moving less sharply than the general index despite its significant fundamental challenges.
Growth & Income
Revenue growth for the year-over-year period stands at -21.7%, while earnings growth is N/A due to the absence of positive historical earnings to compare against. The negative revenue growth combined with N/A earnings growth suggests that the company is contracting its top line, and without positive earnings, the concept of earnings growing faster or slower than revenue is technically inapplicable until profitability is restored. As a non-dividend payer, PetMed Express does not distribute a dividend yield or maintains a payout ratio of 0.0%, meaning the company retains all cash flow internally rather than paying out dividends to shareholders. This lack of dividend income forces investors to rely entirely on potential share price appreciation to generate returns, given that the company currently reinvests its limited resources into operations rather than distributing profits. The overall growth and income profile is characterized by significant revenue contraction, negative earnings, and zero dividend distribution, presenting a challenging landscape for capital preservation and growth.